Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 11:54, 10 February 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wik← Previous edit		Latest revision as of 19:42, 17 May 2024 edit undoBenjah-bmm27 (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers14,702 editsm Reverted edit by Bongoboron (talk) to last version by Maxim MasiutinTags: Rollback Mobile edit Mobile web edit
(176 intermediate revisions by 92 users not shown)
Line 1:		Line 1:
			{{Short description|Pharmaceutical drug}}
	{{drugbox
			{{Use dmy dates|date=March 2024}}
	| verifiedrevid = 412496014
			{{cs1 config|name-list-style=vanc|display-authors=6}}
	| IUPAC_name = (ethanedioato-''O'',''O''')platinum(II)
			{{Drugbox
	| image = Oxaliplatin-2D-skeletal.png | width = 200 px
			| Verifiedfields = changed
	| image2 = Oxaliplatin-3D-balls.png | width2 = 200
			| verifiedrevid = 413092968
	| CAS_number = 63121-00-6
			| image = Oxaliplatin-2D-skeletal.svg
	| ATC_prefix = L01
	| ATC_suffix = XA03		| width = 200
	| ATC_supplemental =		| alt =
			| image2 = Oxaliplatin-from-xtal-Mercury-3D-balls.png
	| PubChem = 77994
	| DrugBank = APRD00186		| width2 = 200
			| alt2 =
			<!-- Clinical data -->
			| pronounce =
			| tradename = Eloxatin
			| Drugs.com = {{drugs.com|monograph|oxaliplatin}}
			| MedlinePlus = a607035
			| DailyMedID = Oxaliplatin
			| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
			| pregnancy_AU_comment =
			| pregnancy_category =
			| routes_of_administration = ]
			| class =
			| ATC_prefix = L01
			| ATC_suffix = XA03
			| ATC_supplemental =
			<!-- Legal status -->
			| legal_AU = S4
			| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017 | access-date=30 March 2024}}</ref>
			| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
			| legal_BR_comment =
			| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
			| legal_CA_comment =
			| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
			| legal_DE_comment =
			| legal_NZ = <!-- Class A, B, C -->
			| legal_NZ_comment =
			| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
			| legal_UK_comment =
			| legal_US = Rx-only
			| legal_US_comment = <ref>{{cite web | title=Eloxatin- oxaliplatin injection, solution, concentrate | website=DailyMed | date=22 October 2019 | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=432559 | access-date=26 May 2022}}</ref>
			| legal_EU =
			| legal_EU_comment =
			| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
			| legal_UN_comment =
			| legal_status = <!-- For countries not listed above -->
			<!-- Pharmacokinetic data -->
			| bioavailability = Complete
			| protein_bound =
			| metabolism =
			| elimination_half-life = ~10 – 25 minutes<ref>{{cite journal | vauthors = Ehrsson H, Wallin I, Yachnin J | title = Pharmacokinetics of oxaliplatin in humans | journal = Medical Oncology | volume = 19 | issue = 4 | pages = 261–265 | year = 2002 | pmid = 12512920 | doi = 10.1385/MO:19:4:261 | s2cid = 1068099 }}</ref>
			| excretion = ]
			<!-- Identifiers -->
			| CAS_number_Ref = {{cascite|changed|??}}
			| CAS_number = 61825-94-3
			| PubChem = 77994
			| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
			| DrugBank = DB00526
			| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
			| ChemSpiderID = 8062727
			| UNII_Ref = {{fdacite|changed|FDA}}
			| UNII = 04ZR38536J
	| KEGG_Ref = {{keggcite|correct|kegg}}		| KEGG_Ref = {{keggcite|correct|kegg}}
	| KEGG = D01790		| KEGG = D01790
			| ChEMBL_Ref = {{ebicite|changed|EBI}}
			| ChEMBL = 414804
			| PDB_ligand = 1PT
			<!-- Chemical and physical data -->
			| IUPAC_name = (ethanedioato-''O'',''O''')platinum(II)
	| C=8 | H=14 | N=2 | O=4 | Pt=1		| C=8 | H=14 | N=2 | O=4 | Pt=1
			| SMILES = O1C(=O)C(=O)O12C0CCCCC02
	| molecular_weight = 397.2858 g/mol
			}}
	| bioavailability = Complete
	| protein_bound =
	| metabolism =
	| elimination_half-life = ~10 - 25 minutes <ref>Ehrsson H, Wallin I, Yachnin J. ''Medical Oncology''. 2002; '''19''':251-265.</ref>
	| pregnancy_category =
	| legal_status =
	| routes_of_administration = Intravenous
	| excretion = Renal }}
			<!-- Definition and medical uses -->
	'''Oxaliplatin''' is a ] that is used in cancer ]. These ]-based drugs are usually classified as ], although they are not actually ]ating groups (they function by a similar mechanism).<ref>Direct Cellular Responses to Platinum-Induced DNA Damage. Yongwon Jung and Stephen J. Lippard, Chem. Rev., 107, 1387-1407 (2007).{{DOI|10.1021/cr068207j}}</ref>
			'''Oxaliplatin''', sold under the brand name '''Eloxatin''' among others, is a ] (] class) used to treat ].<ref name=AHFS2016/> It is given by ].<ref name=AHFS2016>{{cite web|title=Oxaliplatin|url=https://www.drugs.com/monograph/oxaliplatin.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161221013453/https://www.drugs.com/monograph/oxaliplatin.html|archive-date=21 December 2016}}</ref>
			<!-- Side effect and mechanisms -->
	==Preparation and structure==
			Common side effects include ], feeling tired, nausea, diarrhea, and ].<ref name=AHFS2016/><ref name=Ou2018>{{cite journal | vauthors = Oun R, Moussa YE, Wheate NJ | title = The side effects of platinum-based chemotherapy drugs: a review for chemists | journal = Dalton Transactions | volume = 47 | issue = 19 | pages = 6645–6653 | date = May 2018 | pmid = 29632935 | doi = 10.1039/c8dt00838h }}</ref> Other serious side effects include ].<ref name=Ou2018/><ref name=AHFS2016/> Use in ] is known to harm the baby.<ref name=AHFS2016/> Oxaliplatin is in the ] family of medications.<ref name=App2015>{{cite journal | vauthors = Apps MG, Choi EH, Wheate NJ | title = The state-of-play and future of platinum drugs | journal = Endocrine-Related Cancer | volume = 22 | issue = 4 | pages = R219–R233 | date = August 2015 | pmid = 26113607 | doi = 10.1530/ERC-15-0237 | doi-access = free | hdl = 2123/24426 | hdl-access = free }}</ref> It is believed to work by blocking the duplication of ].<ref name=AHFS2016/>
	Oxaliplatin was discovered in 1976 at ] by Professor Yoshinori Kidani, who was granted U.S. Patent 4,169,846 in 1979. Oxaliplatin was subsequently in-licensed by ] and developed as an advanced colorectal cancer treatment. Debio licensed the drug to ] in 1994. Eloxatin gained European approval in 1996 (firstly in France) and approval by the ] (FDA) in 2002.
			<!-- History and culture -->
	The compound features a ] platinum(II) center. In contrast to ] and ], oxaliplatin features the ] ligand ] in place of the two ] ammine ]s. It also features a bidentate oxalate group.
			Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe.<ref name=Fis2006>{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=513|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA513|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220163817/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA513|archive-date=20 December 2016}}</ref> It is on the 2023 ].<ref name="WHO23rd">{{cite book |title=The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) |vauthors=((World Health Organization)) |publisher=World Health Organization |year=2023 |location=Geneva |hdl=10665/371090 |id=WHO/MHP/HPS/EML/2023.02 |author-link=World Health Organization |hdl-access=free}}</ref>
	== Mechanism of action ==		== Medical uses ==
			Oxaliplatin is used for treatment of ], typically along with ] (leucovorin) and ] in a combination known as ]<ref name="NCI FOLFOX">{{cite web | title=FOLFOX | website=National Cancer Institute | date=18 September 2009 | url=https://www.cancer.gov/about-cancer/treatment/drugs/folfox | access-date=26 May 2022}}</ref> or along with ] in a combination known as ]<ref name="NCI CAPOX">{{cite web | title=CAPOX | website=National Cancer Institute | date=4 April 2012 | url=https://www.cancer.gov/about-cancer/treatment/drugs/capox | access-date=26 May 2022}}</ref> or ].<ref name="NCI XELOX">{{cite web | title=XELOX | website=National Cancer Institute | date=6 January 2012 | url=https://www.cancer.gov/about-cancer/treatment/drugs/xelox | access-date=26 May 2022}}</ref> It may also be effective against ], ], ], ], and ].<ref>{{Cite book |title=xPharm: The Comprehensive Pharmacology Reference |vauthors=Townsend D |publisher=Elsevier |year=2007 |chapter=Oxaliplatin |pages=1–4 |doi=10.1016/B978-008055232-3.62973-3|isbn=9780080552323 }}</ref>
	The cytotoxicity of platinum compounds is thought to result from inhibition of DNA synthesis in cancer cells.
	In vivo studies showed that Oxaliplatin has anti-tumor activity against colon carcinoma through its (non-targeted) ] effects.
	== Clinical use ==
	Oxaliplatin is typically administered with ] and ] in a combination known as ] for the treatment of ]. Oxaliplatin is marketed by ] under the trademark '''Eloxatin''' or by Medac GmbH under the trademark '''Oxaliplatin Medac'''. There are generic equivalents on the market now <ref>Generic Oxaliplatin Approved</ref> Oxaliplatin has been compared with other platinum compounds (Cisplatin, Carboplatin) in advanced cancers (gastric, ovarian).
	=== Advanced colorectal cancer ===		=== Advanced colorectal cancer ===
	In clinical studies, Oxaliplatin by itself has modest activity against advanced colorectal cancer.<ref>Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16(8):2739-44. PMID 9704726.</ref> It has been extensively studied in combination with Fluorouracil and Folinic Acid (a combination known as FOLFOX). When compared with Fluorouracil and Folinic Acid administered according to the "De Gramont regimen" there was no significant increase in overall survival with the FOLFOX regimen (specifically, FOLFOX4), but progression-free survival, the primary end-point of the phase III randomized trial, was improved with FOLFOX.<ref>de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16):2938-47. PMID 10944126</ref>		Oxaliplatin by itself has modest activity against advanced colorectal cancer.<ref name="pmid9704726">{{cite journal | vauthors = Bécouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-André G, Rougier P | title = Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers | journal = Journal of Clinical Oncology | volume = 16 | issue = 8 | pages = 2739–2744 | date = August 1998 | pmid = 9704726 | doi = 10.1200/JCO.1998.16.8.2739 }}</ref> When compared with just ] and ] administered according to the ], a FOLFOX4 regime produced no significant increase in overall survival, but did produce an improvement in ], the primary end-point of the phase III randomized trial.<ref name="pmid10944126">{{cite journal | vauthors = de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A | title = Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | journal = Journal of Clinical Oncology | volume = 18 | issue = 16 | pages = 2938–2947 | date = August 2000 | pmid = 10944126 | doi = 10.1200/JCO.2000.18.16.2938 }}</ref>
	=== Adjuvant treatment of colorectal cancer ===
	After the curative resection of colorectal cancer, chemotherapy based on Fluorouracil and folinic acid reduces the risk of relapse. The benefit is clinically relevant when cancer has spread to locoregional lymph nodes (stage III, Dukes C). The addition of Oxaliplatin improves relapse-free survival, but data on overall survival have not yet been published ''in extenso''. <br />
	When cancer has '''not''' spread to the locoregional lymph nodes (stage II, Dukes B) the benefit of chemotherapy is marginal and the decision on whether to give adjuvant chemotherapy should be carefully evaluated by discussing with the patient the realistic benefits and the possible toxic side effects of treatment. This is even more relevant when the oncologist proposes treatment with Oxaliplatin.
	== Adverse effects ==		== Adverse effects ==
	Side-effects of oxaliplatin treatment can potentially include:		Side-effects of oxaliplatin treatment can potentially include:
			* ] leading to ], a progressive, enduring and often irreversible tingling numbness, intense pain and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs, often with deficits in ].<ref name=pasetto>{{cite journal | vauthors = Pasetto LM, D'Andrea MR, Rossi E, Monfardini S | title = Oxaliplatin-related neurotoxicity: how and why? | journal = Critical Reviews in Oncology/Hematology | volume = 59 | issue = 2 | pages = 159–168 | date = August 2006 | pmid = 16806962 | doi = 10.1016/j.critrevonc.2006.01.001 }}</ref> This chronic neuropathy may also be preceded by a transient acute neuropathy occurring at the time of infusion and associated with excitation of ].<ref name="pmid16231011">{{cite journal | vauthors = Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A | title = Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels | journal = British Journal of Pharmacology | volume = 146 | issue = 7 | pages = 1027–1039 | date = December 2005 | pmid = 16231011 | pmc = 1751225 | doi = 10.1038/sj.bjp.0706407 }}</ref><ref name="pmid29649985">{{cite journal | vauthors = Gebremedhn EG, Shortland PJ, Mahns DA | title = The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review | journal = BMC Cancer | volume = 18 | issue = 1 | pages = 410 | date = April 2018 | pmid = 29649985 | pmc = 5897924 | doi = 10.1186/s12885-018-4185-0 | doi-access = free }}</ref>
	* ], (both an acute, reversible sensitivity to cold and numbness in the hands and feet and a chronic, possibly irreversible foot/leg, hand/arm numbness, often with deficits in ])<ref name=pasetto>Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. Pub. June 27, 2006. PMID 16806962.</ref>
	* ]		* ]
	* ], ], and/or ]		* ], ], or ]
	* ]		* ] (low number of a type of white blood cells)
	* ] (hearing loss)		* ] (hearing loss)
	* ] if Oxaliplatin leaks from the infusion vein it may cause severe damage to the connective tissues.		* ] if oxaliplatin leaks from the infusion vein it may cause severe damage to the connective tissues.
	* ], which is more common in women than men <ref name=chay>Chay‌ WY, Chew‌ L, Yeoh TT, Tan MH. An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women. Acta Oncologica. May 2010, Vol. 49, No. 4, Pages 515-517. PMID: 20092386.</ref>		* ] (low blood potassium), which is more common in women than men<ref name=chay>{{cite journal | vauthors = Chay WY, Chew L, Yeoh TT, Tan MH | title = An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women | journal = Acta Oncologica | volume = 49 | issue = 4 | pages = 515–517 | date = May 2010 | pmid = 20092386 | doi = 10.3109/02841860903464015 | s2cid = 33026126 | doi-access = free }}</ref>
			* Persistent ]<ref>{{cite web |url=https://www.drugs.com/sfx/oxaliplatin-side-effects.html | work = Drugs.com |title=Oxaliplatin Side Effects |access-date=5 September 2014 |url-status=live |archive-url= https://web.archive.org/web/20140905140215/http://www.drugs.com/sfx/oxaliplatin-side-effects.html |archive-date=5 September 2014 }}</ref>
			* ]<ref>{{cite web |url=https://mein.sanofi.de/produkte/Eloxatin/Downloads?id=dafcc9b3-4397-4205-aeb3-581a3fa90edd |title=Eloxatin information |access-date=15 June 2016 |url-status=live |archive-url=https://web.archive.org/web/20160827232728/https://mein.sanofi.de/produkte/Eloxatin/Downloads?id=dafcc9b3-4397-4205-aeb3-581a3fa90edd |archive-date=27 August 2016 |language=de | work = mein.sanofi.de }}</ref>
	In addition, some patients may experience an ] to platinum-containing drugs. This is more common in women.<ref name=chay/>		In addition, some patients may experience an ] to platinum-containing drugs. This is more common in women.<ref name=chay/>
	Oxaliplatin has less ototoxicity and ] than cisplatin and carboplatin.<ref name=pasetto/>		Oxaliplatin has less ototoxicity and ] than cisplatin and carboplatin.<ref name=pasetto/>
			== Structure and mechanism ==
			The compound features a ] platinum(II) center. In contrast to other drugs of the ] class of drugs ] and ], oxaliplatin features the ] ligand ] in place of the two ] ammine ]s. It also features a bidentate ] group.<ref name=App2015/> The three-dimensional structure of the molecule has been elucidated by X-ray crystallography, although the presence of pseudosymmetry in the crystal structure has caused confusion in its interpretation.<ref>{{cite journal | vauthors = Johnstone TC | title = The Crystal Structure of Oxaliplatin: A Case of Overlooked Pseudo Symmetry | journal = Polyhedron | volume = 67 | pages = 429–435 | date = January 2014 | pmid = 24415827 | pmc = 3885251 | doi = 10.1016/j.poly.2013.10.003 }}</ref>
			According to '']'' studies, oxaliplatin fights ] of the ] through non-targeted ] effects. Like other platinum compounds, its cytotoxicity is thought to result from inhibition of ] in cells. In particular, oxaliplatin forms both inter- and intra-strand cross links in DNA,<ref>{{cite journal | vauthors = Graham J, Mushin M, Kirkpatrick P | title = Oxaliplatin | journal = Nature Reviews. Drug Discovery | volume = 3 | issue = 1 | pages = 11–12 | date = January 2004 | pmid = 14756144 | doi = 10.1038/nrd1287 }}</ref> which prevent DNA replication and transcription, causing cell death.
			==History==
			Oxaliplatin was first synthesized in 1978 at ] by Yoshinori Kidani.<ref>{{Cite book |title=Comprehensive Inorganic Chemistry II |vauthors=Pizarro AM, Barry NP, Sadler PJ |publisher=Elsevier |year=2013 |edition=2nd |pages=751–784 |chapter=3.25 - Metal–DNA Coordination Complexes |doi=10.1016/B978-0-08-097774-4.00330-2|isbn=9780080965291 }}</ref> It was later developed in Europe as a less toxic and more effective alternative to cisplatin. It gained European approval in 1996,<ref>{{Cite book |title=Radiation Oncology |publisher=Mosby |year=2010 |isbn=978-0-323-04971-9 |vauthors=Janjan NA, Delclos ME, Crane CH, Krishnan S, Das P |edition=9th |pages=560–605 |chapter=Chapter 24 - The Colon and Rectum}}</ref> and approval by the ] in 2002.<ref>{{Cite web |title=Eloxatin FDA Approval History |url=https://www.drugs.com/history/eloxatin.html |website=Drugs.com}}</ref> ] oxaliplatin was first approved in the United States in August 2009.<ref>{{cite web | url=https://www.drugs.com/availability/generic-eloxatin.html | title=Generic Eloxatin availability | publisher=] | access-date=19 April 2014 | url-status=live | archive-url=https://web.archive.org/web/20130607135331/http://www.drugs.com/availability/generic-eloxatin.html | archive-date=7 June 2013 }}</ref> Patent disputes caused generic production to stop in 2010, but it restarted in 2012.<ref>{{cite press release |url=http://www.prnewswire.com/news-releases/hospira-announces-us-re-launch-of-generic-oxaliplatin-injection-165568176.html |title=Hospira Announces U.S. Re-Launch Of Generic Oxaliplatin Injection |access-date=25 August 2015 |url-status=live |archive-url=https://web.archive.org/web/20150924145942/http://www.prnewswire.com/news-releases/hospira-announces-us-re-launch-of-generic-oxaliplatin-injection-165568176.html |archive-date=24 September 2015 }}</ref><ref>{{cite web | url=http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs/eloxatin-12-billion | title=Top 10 best-selling cancer drugs: Eloxatin–$1.2 billion | work=FiercePharma | date=15 May 2012 | access-date=20 April 2014 | url-status=live | archive-url=https://web.archive.org/web/20140421064504/http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs/eloxatin-12-billion | archive-date=21 April 2014 }}</ref>
	== Patent information ==		== Patent information ==
	Eloxatin is covered by patent numbers 5338874 (Expiry Apr 07,2013), 5420319 (Expiry Aug 08,2016), 5716988 (Expiry Aug 07,2015) and 5290961 (Expiry Jan 12, 2013) (see Electronic Orange Book patent info for Eloxatin).<ref name="Appl No 021759">Orange Book. accessdata.fda.gov. URL: . Accessed on: July 22, 2007.</ref> Exclusivity code I-441, which expired on Nov 04, 2007, is for use combination with infusional 5-FU/LV for adjuvant treatment stage III colon cancer patients who have undergone complete resection primary tumor-based on improvement in disease free survival with no demonstrated benefit overall survival after 4 years. Exclusivity code NCE, New Chemical Entity, expired on Aug 09, 2007.<ref name="Appl No 021759"/>		Eloxatin was covered by patent numbers 5338874 (expired 7 April 2013), 5420319 (expired 8 August 2016), 5716988 (expired 7 August 2015) and 5290961 (expired 12 January 2013) (see Electronic Orange Book patent info for Eloxatin).<ref name="Appl No 021759">{{cite web | work = Orange Book | publisher = U.S. Food and Drug Administrartion | title = Patent and Exclusivity Search Results from query on Appl No 021759 Product 001 in the OB_Rx list. | url = http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021759&Product_No=001&table1=OB_Rx | archive-url = https://web.archive.org/web/20070926221724/http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021759&Product_No=001&table1=OB_Rx | archive-date=26 September 2007 }}. Accessed on: 22 July 2007.</ref> Exclusivity code I-441, which expired on 4 November 2007, is for use combination with infusional 5-FU/LV for adjuvant treatment stage III colon cancer patients who have undergone complete resection primary tumor-based on improvement in disease free survival with no demonstrated benefit overall survival after 4 years. Exclusivity code NCE, New Chemical Entity, expired on 9 August 2007.<ref name="Appl No 021759"/>
	== References ==		== References ==
			{{reflist}}
	<references/>
			== Further reading ==
	==External links==
			{{refbegin}}
	* - Official web site of manufacturer.
			* {{cite journal | vauthors = Graham J, Mushin M, Kirkpatrick P | title = Oxaliplatin | journal = Nature Reviews. Drug Discovery | volume = 3 | issue = 1 | pages = 11–12 | date = January 2004 | pmid = 14756144 | doi = 10.1038/nrd1287 | url = http://www.dresources.com/nature/ntr_0104.pdf | access-date = 19 July 2005 | url-status = dead | archive-url = https://web.archive.org/web/20041108160042/http://www.dresources.com/nature/ntr_0104.pdf | archive-date = 8 November 2004 }}
	* - Official prescribing information.
			{{refend}}
	*
	*
			== External links ==
	==Additional sources==
	* {{cite journal | jill = Graham J, Mushin M, Kirkpatrick P | title = Oxaliplatin. | journal = Nat Rev Drug Discov | volume = 3 | issue = 1 | pages = 11–2 | year = 2004 | pmid = 14756144 | url=http://www.dresources.com/nature/ntr_0104.pdf | format=PDF}}		* {{cite web | title=Oxaliplatin | website=National Cancer Institute | date=5 October 2006 | url=https://www.cancer.gov/about-cancer/treatment/drugs/oxaliplatin }}
	{{Chemotherapeutic agents}}		{{Chemotherapeutic agents}}
			{{Platinum compounds}}
			{{Portal bar|Medicine}}
	]		]
	]		]
	]
	]		]
			]
			]
	]
			]
	]
			]
	]
			]
	]
	]
	]
	]
	]